Clinical Trials List
2021-09-01 - 2025-04-30
Phase II
Recruiting2
ICD-10C96.9
Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
ICD-10C96.Z
Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9202.98
Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue, lymph nodes of multiple sites
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Ming-Chung Kao Division of Hematology & Oncology
- Po-Nan Wang 未分科
- Tung-Liang Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
9 participants
-
Global
180 participants
